SCM
BIOR

Stonepine Capital Management’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Stonepine Capital Management’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-272
Closed -$614K – 22
2020
Q3 		$614K Sell
272
-113
-29% -$256K 0.64% 17
2020
Q2 		$865K Buy
+385
New +$1.05M 1.68% 12

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonepine Capital Management's BIOR Position: Q4 2020 in Review

Stonepine Capital Management sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2020, closing a stake of 272 shares — an estimated $614K sold.

Stonepine Capital Management first reported a position in BIOR in Q2 2020 and held it in 2 quarters. The position peaked at $865K in Q2 2020. 48 funds tracked by Wall St. Rank hold BIOR as of Q4 2020.

  • Stonepine Capital Management reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Stonepine Capital Management sold 272 Biora Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $614K.
  • Stonepine Capital Management first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Stonepine Capital Management's Biora Therapeutics, Inc. Common Stock position peaked at $865K in Q2 2020.
  • 48 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Stonepine Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.